Influenza Strain Articles & Analysis
9 news found
Influenza A virus is a genus of virus in the family Orthomyxoviridae and causes influenza in birds and some mammals. Influenza A virus strains of all subtypes have been isolated from wild birds, but disease is rare. ...
Creative Diagnostics' research team takes advantage of mouse models to study a variety of influenza A virus strains, including H9N2, H1N1 and H3N2. The portfolio offers customized and standard preclinical services to evaluate pathogenesis, humoral responses, and protective efficacy induced by wild-type influenza A viruses or ...
The neutralization test is the most accurate way to determine whether a person has antibodies that can neutralize the infectivity of a particular viral strain. Taking influenza viruses as an example, it detects antibodies targeting HA proteins of influenza viruses, thereby identifying functional strain-specific antibodies in ...
This new study will build on Enesi’s successful Biomedical Advanced Research and Development Authority (BARDA) Drive Beyond the Needle collaboration earlier this year, under which the company successfully developed a number of solid-dose formulations of a recombinant H7N9 pandemic influenza vaccine. Under NIAID’s suite of preclinical services, NIAID-funded ...
Scientists do their best to anticipate the most likely culprits from a constantly evolving cast of viral characters, hoping that their efforts will land effectively in the coming flu season. Predictions of which influenza strains will be circulating each year are made more than six months before the onset of flu season—and even if projections are accurate, ...
EnGen Bio is an early stage biotechnology company developing a new approach to preventing and treating all Type A influenza strains—including all flu pandemics. Seasonal flu causes 50,000–250,000 deaths worldwide annually, causing the World Health Organization to declare the development of a universal flu vaccine as an urgent need in its Global ...
EnGen Bio is an early stage biotechnology company pioneering a new approach to preventing and treating influenza, with the goal of an effective, easy-to-manufacture, shelf-stable universal flu vaccine that should confer long-term immunity to all Type A influenza strains—including all flu pandemics. ...
“The preclinical results we have obtained make us confident in the ability of our IMX313P-based influenza vaccine candidate to improve the effectiveness of current seasonal influenza prevention,” said Alexandre Le Vert, Chief Executive Officer of Imaxio. ...
To achieve this, it will develop a candidate vaccine comprising a recombinant, proprietary, and highly immunogenic version of the influenza virus nucleoprotein (NP). The candidate vaccine from the OPTIVAC project will be administered in conjunction with current influenza vaccines with the aim of improving their efficacy, particularly in the elderly. ...